Recombinant Human Serum Albumin (rHSA)
Optibumin® 20
High-purity recombinant human serum albumin excipient supplied as a 20% w/v liquid.
Optibumin 20 is appropriate for applications where a 20% (w/v) liquid albumin in bottles fits specific formulation or process requirements — including select drug conjugation workflows, and biopharmaceutical formulation.
Composition
- Form
- Liquid
- Purity
- ≥99.0%
- Endotoxin
- ≤0.02 EU/mg
- Storage
- 2 to 8 °C
Compliance
- Status
- AOF, Excipient
- Manufacturing
- cGMP, ISO 9001:2015
- Facility
- Junction City, KS
- Documentation
- Lot-specific CoA
Product overview
A high purity 20% recombinant albumin
for select applications.
Teams formulating, conjugating, and solubilizing with human serum albumin still start from plasma. Plasma-derived HSA is pasteurized at 60 °C for 10 hours, so it ships with typically 16 to 32 mM sodium octanoate and N-acetyl tryptophan added to survive that step. Those stabilizers are active ligands rather than passive additives. They bind with high affinity to specific pockets and may occupy the sites a formulator wants. Roughly 60% of its Cys34 arrives reduced, the rest cysteinylated and unavailable for maleimide chemistry. Aggregate burden varies by supplier, on top of donor-pool variability and adventitious agent risk.
Optibumin® 20 is InVitria’s high-purity 20% w/v recombinant human serum albumin, produced on the animal-free ExpressTec™ platform, a non-mammalian expression host, at the ISO 9001:2015-certified, cGMP-compliant facility in Junction City, Kansas. Purity is ≥99.0% and endotoxin ≤0.02 EU/mg, with no stabilizers and no preservatives. It ships ready to use in 100 mL and 1L bottles.

Featured Resources
The published data behind the claims
Regulatory precedent
The rHSA platform behind ERVEBO®.
Merck’s ERVEBO® Ebola vaccine, the first FDA- and EMA-approved Ebola vaccine, uses rHSA from InVitria’s recombinant-albumin platform.

Technical specifications
| Attribute | Value |
|---|---|
| Physical & Chemical | |
| Form | Liquid |
| Formulation | Buffered salt-based solution |
| Concentration | 200 mg/mL (20% w/v) |
| Appearance | Slightly yellow/amber solution |
| Molecular weight | ~66.5 kDa |
| Purity | ≥99.0% |
| Endotoxin level | ≤0.02 EU/mg |
| Sterility | Sterile (0.2 µm sterile filtered) |
| Storage conditions | 2 to 8 °C |
| Shelf life | 3 years from DOM (liquid) |
| Packaging | 100 mL and 1 L bottles |
| Composition | |
| Product name | Optibumin® 20 |
| Brand | InVitria® |
| SKU / Product Number | 777HSA105 |
| Protein | Recombinant Human Serum Albumin (rHSA) |
| Class | Serum Protein / Albumin, Excipient |
| Synonyms | rHSA, HSA, ALB, Albumin, Human Albumin, SA, rHA |
| Expression system | Recombinant, Animal-Origin Free |
| Stabilizers/Preservatives | None |
| Regulatory | |
| Production standard | ISO 9001:2015, cGMP-compliant facility |
| Country of origin | USA (Junction City, KS) |
| Documentation | Certificate of Analysis (request form) · Data Sheet · Guidelines for Use · Safety Data Sheet · Certificate of Origin and Animal-Free / TSE-BSE Statement · ISO 9001:2015 certificate · cGMP Statement · product-specific Technical Summary on request |
Key Benefits
- Ready-to-Use 20% Liquid
- Optibumin® 20: sterile 20% w/v liquid in 100 mL and 1 L bottles, with no reconstitution.
- ~3x Higher Drug Binding
- Warfarin KD of 2.58 µM versus 7.45 µM for plasma HSA at Sudlow site I.
- ~3x Higher Maleimide Conjugation
- ~99% reduced Cys34 versus ~60% in plasma HSA supports defined-stoichiometry conjugation.
- Low Aggregates, Tight Lot Consistency
- Mean 0.47% aggregates across 15 lots, versus 7.52% across 8 plasma HSA lots.
How to order Optibumin® 20
- Catalog purchase
- 100 mL at $1,660 and 1 L at $14,800, added to cart from the product page. Both ship as the ready-to-use sterile 20% w/v liquid in bottles.
- Purchase Order
- Contact info@invitria.com or a Product Applications team member at InVitria to submit a PO directly.
- Bulk pricing
- Bulk and commercial-scale supply runs direct with InVitria, with GMP supply commitments and regulatory documentation support. Request a quote through the bulk pricing form. Contact InVitria for bulk and custom packaging beyond the 100 mL and 1 L bottles.
- Regional distribution
- Optibumin 20 is available worldwide. Most customers work directly with InVitria for full portfolio access and bulk and commercial-scale supply. European customers can order with direct fulfillment from InVitria’s Rotterdam, Netherlands facility. To buy through a regional distributor, use the Find a Distributor form.
A Certificate of Analysis is issued for every lot and is available through the request form. Data Sheet, Guidelines for Use, Safety Data Sheet, ISO 9001:2015 certificate, and cGMP Statement are published documents, with a product-specific Technical Summary on request. TSE/BSE statement and Certificate of Origin are published resources.
Common questions
Optibumin 20 is a chemically defined, animal-origin-free recombinant human serum albumin supplied as a sterile 20% w/v liquid in 100 mL and 1 L bottles. It is part of InVitria’s Optibumin line, sharing the same ExpressTec™ expression platform, ≥99.0% purity, stabilizer-free composition, and approximately 99% reduced Cys34 thiol as Optibumin 25.
Optibumin 20 is produced recombinantly on InVitria’s ExpressTec expression platform, a non-mammalian, non-human expression host with no animal-derived, human-derived, or blood-derived materials. Manufacturing is fully animal-origin-free, from raw materials through production equipment to product-contact packaging. Optibumin 20 is manufactured without the stabilizers plasma-derived HSA pasteurization requires, no sodium octanoate and no N-acetyl tryptophan, which gives a native-state molecule without the harsh thermal treatment that renders plasma HSA safe for injection.
Yes. InVitria manufactures Optibumin 20 under a cGMP-compliant quality management system with respect to 21 CFR Part 210/211 at its ISO 9001:2015-certified facility in Junction City, Kansas, USA. Optibumin 20 is 100% animal-origin-free. Raw materials, production host, manufacturing equipment, and product-contact packaging are all free of animal-derived components.
Optibumin 20 is supplied as a sterile 20% w/v liquid with purity ≥99.0%, endotoxin ≤0.02 EU/mg, and approximately 99% reduced Cys34 thiol, which is what maleimide-based bioconjugation and drug binding depend on.
Optibumin 20 is supported by a Certificate of Analysis, Safety Data Sheet, Guidelines for Use, Certificate of Origin and Animal-Free / TSE-BSE Statement, ISO 9001 certificate, and cGMP Statement. Additional quality and regulatory documentation is available on request, including materials for IND-supporting packages and supplier qualification.
InVitria provides a product-specific Technical Summary for Optibumin 20 containing CMC-style documentation: manufacturing process, raw material controls, characterization data, release specifications, and lot analysis. It is designed to support customer regulatory submissions globally, including IND, BLA, and comparable filings under FDA, EMA, and other regulatory authorities. Unlike a Drug Master File, the Technical Summary goes directly to the customer for incorporation into their own documentation, giving full visibility into the CMC information without being tied to a single regulatory pathway. It is supported by per-lot Certificates of Analysis, Animal-Origin-Free / TSE-BSE statements, ISO 9001 certification, cGMP statements, and change notification under defined policies. Contact us to request it.
Yes. The Optibumin platform shows approximately 3x higher drug binding affinity at Sudlow site I than plasma-derived HSA, KD 2.58 µM against 7.45 µM with warfarin, p < 0.01 by Fisher’s F-test. Three things drive it: the absence of the stabilizers sodium octanoate and N-acetyl tryptophan, which interfere with drug binding; approximately 10x fewer aggregates, which preserves accessible surface area; and approximately 99% reduced Cys34 against ~60% in plasma HSA. These advantages apply to both Optibumin 20 and Optibumin 25 because they characterize the rHSA molecule itself, not the product concentration.
Both are liquid rHSAs from the same ExpressTec platform, sharing ≥99.0% purity, stabilizer-free composition, approximately 99% reduced Cys34, and an animal-origin-free profile. Optibumin 20 is a 20% w/v liquid in 100 mL and 1 L bottles, for drug conjugation, biopharmaceutical formulation at 20%, IVF and assisted reproduction, and select stem cell research. Optibumin 25 is a 25% w/v liquid, matching plasma-derived HSA concentration, in 100 mL bottles and closed-system bags with weldable tubing. For cell and gene therapy manufacturing, particularly closed-system workflows, cryopreservation, and direct replacement of 25% plasma-derived HSA, Optibumin 25 is InVitria’s recommended product. Where a 20% liquid albumin in bottles is appropriate, Optibumin 20 is the correct product. Contact InVitria to discuss the best option.
Both are cGMP excipient recombinant human serum albumins from the same ExpressTec platform, differing in physical format and regulatory history. Optibumin 20 is a high-purity (≥99.0%) 20% w/v liquid in bottles, for drug conjugation, biopharmaceutical formulation, IVF, and select stem cell research. Exbumin is a lyophilized powder with regulatory precedent in an approved injectable human biologic: a formulation component in Merck’s ERVEBO Ebola vaccine, approved as an excipient by the FDA and EMA. Choose Exbumin when precedent in an approved injectable is required, or a lyophilized powder suits your formulation or stability requirements. For conjugation, formulation, or research where a 20% liquid albumin is appropriate, Optibumin 20 is the correct product. Contact InVitria to discuss the best option.
Optibumin 20 is a liquid rHSA for drug conjugation, biopharmaceutical formulation, IVF, and stem cell research. Cellastim S is the cell culture-grade rHSA, a lyophilized powder for serum-free media supplementation and cell cryopreservation, with specifications set for that application. If you are supplementing cell culture media, Cellastim S is appropriate. If you are conjugating, formulating, or running research workflows where a 20% liquid albumin fits, Optibumin 20 is the correct product.
Yeast-derived recombinant albumins addressed the pathogen risk of plasma HSA but introduced new issues: immunogenic yeast host cell proteins requiring extensive purification, and surfactants like Polysorbate 80 added to prevent processing aggregation. Optibumin 20’s non-mammalian, non-yeast ExpressTec expression system produces a native-state molecule without those constraints.
Yes. Albumin’s binding capacity for hydrophobic drugs, across two main Sudlow sites, drug binding site III, and seven fatty acid binding sites, makes it a carrier for drugs that would otherwise require toxic organic solvents. Optibumin 20’s ultra-low lipid content, stabilizer-free composition, and aggregate-depleted structure maximize the accessible binding capacity.
Yes. Ultra-low lipid content, chemically defined composition, and the absence of stabilizers suit embryo culture and assisted reproductive technology protocols. The animal-origin-free profile removes the pathogen transmission concerns that come with the serum-derived albumin traditionally used in IVF media, and recombinant production delivers the consistency reproductive medicine research and clinical applications require.
Yes. Optibumin 20 supports iPSC, MSC, and other stem cell culture workflows where a 20% liquid albumin is appropriate, as a chemically defined, animal-origin-free alternative to plasma-derived and serum-derived albumin. Consistent lot-to-lot performance removes the variability that blood-sourced materials introduce into stem cell research.
Optibumin 20 is available as a sterile 20% w/v liquid in 100 mL and 1 L bottles. For cell and gene therapy manufacturing workflows that need a closed-system bag format, Optibumin 25 is available in 100 mL bags with weldable tubing. Contact InVitria for bulk and custom packaging options.
Optibumin 20 is available worldwide through multiple purchasing pathways. Most customers work directly with InVitria for full access to the Optibumin 20 product portfolio, bulk and commercial-scale supply, GMP supply commitments, and regulatory documentation support. European customers can order with direct fulfillment from InVitria’s Rotterdam, Netherlands facility. All customers receive the same product, Certificate of Analysis, and technical support regardless of channel. Contact InVitria or request bulk pricing to place an order.
Store Optibumin 20 at 2 to 8 °C per the Guidelines for Use and the product Certificate of Analysis. Handle aseptically when removing aliquots from the primary container and minimize temperature excursions to preserve product performance. Shelf life is 3 years from date of manufacture. Contact InVitria technical support for application-specific handling guidance.
Use the Certificate of Analysis request form. A Certificate of Analysis is issued for every lot. Additional quality and regulatory documentation, including materials for IND-supporting packages and supplier qualification, is available on request.
Optibumin® 20 is built for these applications
Compare across the rHSA family
| Concentration | Lyophilized powder, reconstitute to 10 to 20% w/v | 25% w/v sterile liquid | 20% w/v sterile liquid | Lyophilized powder, reconstitute to 10 to 20% w/v | 25% w/v sterile liquid |
|---|---|---|---|---|---|
| Format | 10 g, 100 g + scale | 100 mL closed-system bag, 100 mL bottle + scale | 100 mL and 1 L bottles | 10 g, 100 g + scale | 100 mL bottle + scale |
| Best for | Serum-free cell culture media supplementation | Injectable final-formulation excipient. Closed-system applications; 25% drop-in for plasma HSA | Injectable final-formulation excipient. 20% drop-in for plasma HSA | Injectable excipient rHSA for final formulation where lyophilized powder is preferred. | Stem cell culture (iPSC/MSC/etc), lipid sensitive cell types, In Vitro Fertilization (IVF) |
| Grade | GMP | GMP, Excipient | GMP, Excipient | GMP, Excipient | GMP |
| Explore Cellastim S | Explore Optibumin 25 | Explore Optibumin 20 | Explore Exbumin | Explore Optibumin X |
Talk to Product Applications
Discuss your specific formulation workflow.
InVitria’s Product Applications scientists are available to talk through formulation, concentration, regulatory needs, and scale.